mirikizumab-mrkz 200 MG per 2 ML Auto-Injector

RxCUI: 2703049
RxNorm name: mirikizumab-mrkz 200 MG per 2 ML Auto-Injector
Display name: mirikizumab-mrkz 200 MG per 2 ML Auto-Injector
Full name: mirikizumab-mrkz 200 MG per 2 ML Auto-Injector
Term type: SY
Status: DailyMed mapping
Updated: 2026-06-04 23:38:56

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761279	Omvoh	mirikizumab-mrkz	351(a)	Rx	2026-09-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Omvoh	MIRIKIZUMAB-MRKZ	Eli Lilly and Company	472cbe04-263e-433d-9a0f-58c1b50b715a	2026-06-16	Warnings, Adverse reactions	Exact identifier rxcui: 2703049

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set ID	RxNorm mappings	Terms	SPL version	Label	Effective
472cbe04-263e-433d-9a0f-58c1b50b715a	mirikizumab-mrkz 200 MG in 2 ML Auto-Injector [PSN] · 2 ML mirikizumab-mrkz 100 MG/ML Auto-Injector [SCD] · mirikizumab-mrkz 200 MG per 2 ML Auto-Injector [SY]	3	18	These highlights do not include all the information needed to use OMVOH safely and effectively. See full prescribing information for OMVOH. OMVOH (mirikizumab-mrkz) injection, for intravenous or subcutaneous use Initial U.S. Approval: 2023	20251104